ARS Pharmaceuticals (SPRY) director receives grant of 30,000 stock options at $10.54
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ARS Pharmaceuticals director Pratik Shah received a stock option grant covering 30,000 shares of common stock. The option has an exercise price of $10.54 per share and expires on June 23, 2036. According to the terms, all 30,000 options will vest on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
This is a compensation-related award reported as an acquisition, with no open‑market buying or selling of ARS Pharmaceuticals shares disclosed in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Shah Pratik
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 30,000 options
Exercise price: $10.54 per share
Underlying shares: 30,000 shares
+3 more
6 metrics
Option grant size
30,000 options
Stock Option (right to buy) granted to director
Exercise price
$10.54 per share
Conversion or exercise price of stock option
Underlying shares
30,000 shares
Common stock underlying the option grant
Post-grant option holdings
30,000 options
Total derivative securities following transaction
Vesting date
Earlier of June 24, 2027 or 2027 annual meeting
Footnote describes full vesting condition
Expiration date
June 23, 2036
Option expiration date
Key Terms
Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 10.5400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to the option will vest in full on the earlier of June 24, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did ARS Pharmaceuticals (SPRY) director Pratik Shah report on this Form 4?
Director Pratik Shah reported receiving a stock option grant for 30,000 shares of ARS Pharmaceuticals common stock. The award is a compensation-related acquisition, not an open-market trade, and gives him the right to buy future shares at a fixed exercise price.
What are the key terms of Pratik Shah’s ARS Pharmaceuticals (SPRY) stock option grant?
The option covers 30,000 underlying common shares at a $10.54 exercise price per share. It expires on June 23, 2036. These terms define how many shares he may purchase, at what price, and the latest date he can exercise the option.
When do the ARS Pharmaceuticals (SPRY) options granted to Pratik Shah vest?
All 30,000 options will vest in full on the earlier of June 24, 2027 or the date of ARS Pharmaceuticals’ 2027 annual meeting of stockholders. This vesting schedule means the award is not immediately exercisable but becomes fully exercisable at that future date.
How many ARS Pharmaceuticals (SPRY) options does Pratik Shah hold after this grant?
After this transaction, Pratik Shah holds 30,000 stock options according to the filing. These options are tied to ARS Pharmaceuticals common stock and become exercisable after vesting under the specified 2027 vesting conditions described in the footnote.